Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...

AbbVie's cancer drug has received federal approval to treat a kind of follicular lymphoma, potentially a major change in how the disease is treated.

The approval puts Lunsumio on the same footing as Epkinly (epcoritamab) in FL – a form of non-Hodgkin lymphoma (NHL) – as ...

Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for ...

Epcoritamab, rituximab, and lenalidomide combination is approved for relapsed/refractory follicular lymphoma, marking a first in bispecific antibody second-line treatments. The EPCORE FL-1 study ...

As PET scans fall short, blood-based circulating tumor DNA testing shows promise in monitoring large B-cell lymphoma ...

NSHL is the most common type of Hodgkin’s lymphoma and mostly affects children and young adults. It’s highly curable with prompt treatment, so recognizing the symptoms is crucial. Hodgkin’s lymphoma ...

In a heartfelt announcement that has resonated with sports fans across Australia, beloved NRL broadcaster Darryl Brohman has revealed that he has commenced treatment for non-Hodgkin’s lymphoma. Known ...

Non-Hodgkin's lymphoma is a diverse group of blood cancers that includes any lymphoma except Hodgkin's lymphomas. It primarily affects the lymphatic system, which plays a crucial role in the immune ...

Radio personality Darryl Brohman, Big Marn, has revealed his non-Hodgkin's lymphoma diagnosis. He shared the news with ...